11/28
12:15 pm
kros
Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.
Low
Report
Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.
11/26
07:03 pm
kros
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]
Low
Report
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]
11/20
04:37 pm
kros
Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]
Medium
Report
Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]
11/20
04:01 pm
kros
Keros Therapeutics Announces Final Results of Tender Offer
Medium
Report
Keros Therapeutics Announces Final Results of Tender Offer
11/19
06:00 am
kros
Keros Therapeutics Announces Preliminary Results of Tender Offer
Medium
Report
Keros Therapeutics Announces Preliminary Results of Tender Offer
11/12
12:22 pm
kros
Keros Therapeutics (NASDAQ:KROS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $27.00 price target on the stock, up previously from $23.00.
Low
Report
Keros Therapeutics (NASDAQ:KROS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $27.00 price target on the stock, up previously from $23.00.
11/11
09:44 am
kros
Keros Therapeutics (NASDAQ:KROS) had its price target lowered by analysts at Wells Fargo & Company from $26.00 to $23.00. They now have an "overweight" rating on the stock.
Low
Report
Keros Therapeutics (NASDAQ:KROS) had its price target lowered by analysts at Wells Fargo & Company from $26.00 to $23.00. They now have an "overweight" rating on the stock.
11/11
07:17 am
kros
Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
11/10
01:22 pm
kros
KROS vs. ARGX: Which Stock Is the Better Value Option? [Yahoo! Finance]
Low
Report
KROS vs. ARGX: Which Stock Is the Better Value Option? [Yahoo! Finance]
11/9
07:03 pm
kros
Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]
Medium
Report
Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]
11/6
08:40 am
kros
Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Wedbush from $15.00 to $16.00. They now have a "neutral" rating on the stock.
Medium
Report
Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Wedbush from $15.00 to $16.00. They now have a "neutral" rating on the stock.
11/5
04:01 pm
kros
Keros Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Keros Therapeutics Reports Third Quarter 2025 Financial Results
10/20
08:14 am
kros
Keros Therapeutics (NASDAQ:KROS) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $26.00 price target on the stock.
Medium
Report
Keros Therapeutics (NASDAQ:KROS) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $26.00 price target on the stock.
10/20
06:00 am
kros
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
Medium
Report
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
10/15
06:30 am
kros
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Medium
Report
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
9/25
10:16 am
kros
Keros Therapeutics: A Potential Dart Throw [Seeking Alpha]
Low
Report
Keros Therapeutics: A Potential Dart Throw [Seeking Alpha]
9/8
08:25 am
kros
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting [Yahoo! Finance]
9/8
08:00 am
kros
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Low
Report
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting